• Western blot analysis of lysates from COS7 cells, treated with sorbitol 0.4M 24h, using NF-kappaB p65 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using NF-kappaB p65 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Immunofluorescence analysis of HeLa cells, using NF-kappaB p65 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Western blot analysis ofmouse braincells using NF Kappa B-p65 Polyclonal Antibody diluted at 1:2000
  • Western blot analysis of various cells using NF Kappa B-p65 Polyclonal Antibody diluted at 1:2000
  • Immunofluorescence analysis of Hela cell. 1, NF Kappa B-p65 Polyclonal Antibody (red) was diluted at 1:200 (4°C overnight). Bcl-2 monoclonal antibody (6B5) (green) was diluted at 1:200 (4°C overnight). 2, Goat Anti Rabbit Alexa Fluor 594 Catalog: (NA was diluted at 1:1000 (room temperature, 50min). Goat Anti Mouse Alexa Fluor 488 Catalog: (NA was diluted at 1:1000 (room temperature, 50min).

Anti-RELA antibody (275-324) (STJ94469)

SKU:
STJ94469

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Mouse/Monkey
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Transcription factor p65 (275-324) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:10000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: RELA
Gene ID: 5970
Uniprot ID: TF65_HUMAN
Immunogen Region: 275-324
Specificity: NF Kappa B-p65 Polyclonal Antibody detects endogenous levels of NF Kappa B-p65 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from human NF-kappaB p65. AA range:275-324
Post Translational Modifications Ubiquitinated by RNF182, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response. Polyubiquitinated via 'Lys-29'-linked ubiquitin.leading to lysosomal degradation. Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity. Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP.the phosphorylated and acetylated forms show enhanced transcriptional activity. Phosphorylation at Ser-276 by RPS6KA4 and RPS6KA5 promotes its transactivation and transcriptional activities. Phosphorylation at Ser-75 by herpes simplex virus 1/HHV-1 inhibits NF-kappa-B activation. Reversibly acetylated.the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation at Lys-310 promotes interaction with BRD4. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of Lys-310. Lys-310 is deacetylated by SIRT2. S-nitrosylation of Cys-38 inactivates the enzyme activity. Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity. Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B. Proteolytically cleaved within a conserved N-terminus region required for base-specific contact with DNA in a CPEN1-mediated manner, and hence inhibits NF-kappa-B transcriptional activity.
Function NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Beside its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells. The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. Key transcription factor regulating the IFN response during SARS-CoV-2 infection.
Protein Name Transcription Factor P65
Nuclear Factor Nf-Kappa-B P65 Subunit
Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 3
Database Links Reactome: R-HSA-1169091
Reactome: R-HSA-1810476
Reactome: R-HSA-193692
Reactome: R-HSA-202424
Reactome: R-HSA-209560
Reactome: R-HSA-2559582
Reactome: R-HSA-2871837
Reactome: R-HSA-3134963
Reactome: R-HSA-3214841
Reactome: R-HSA-381340
Reactome: R-HSA-445989
Reactome: R-HSA-448706
Reactome: R-HSA-4755510
Reactome: R-HSA-5603029
Reactome: R-HSA-5607761
Reactome: R-HSA-5607764
Reactome: R-HSA-5621575
Reactome: R-HSA-5660668
Reactome: R-HSA-844456
Reactome: R-HSA-8853884
Reactome: R-HSA-9020702
Reactome: R-HSA-933542
Reactome: R-HSA-9660826
Reactome: R-HSA-9692916
Cellular Localisation Nucleus
Cytoplasm
Nuclear
But Also Found In The Cytoplasm In An Inactive Form Complexed To An Inhibitor (I-Kappa-B)
Colocalized With Ddx1 In The Nucleus Upon Tnf-Alpha Induction
Colocalizes With Gfi1 In The Nucleus After Lps Stimulation
Translocation To The Nucleus Is Impaired In L
Monocytogenes Infection
Alternative Antibody Names Anti-Transcription Factor P65 antibody
Anti-Nuclear Factor Nf-Kappa-B P65 Subunit antibody
Anti-Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 3 antibody
Anti-RELA antibody
Anti-NFKB3 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance